Evidence map›Paper›PMID 38665782›Full record

ArticleTurkish journal of biology = Turk biyoloji dergisi2024

CircRNA LDLR promotes proliferation and aerobic glycolysis of gastric cancer cells by targeting CHD1 with miR-449b-5p.

FanYe Zeng, JunTao Zhao, MengTing Tong, WenTing He, Nan Li, YuXiang Fan, YanHua Zhu, LiPing Zhang, HongLiang Zhang

Open access · diamondAbstract read
In one paragraph

Article in Turkish journal of biology = Turk biyoloji dergisi, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

FanYe ZengDepartment of Oncology, Affiliated Hospital of Traditional Chinese Medicine of Xinjiang Medical University, Urumqi City, Xinjiang Uygur Autonomous Region, China.ORCID https://orcid.org/0009-0004-2795-8902
JunTao ZhaoDepartment of Oncology, Affiliated Hospital of Traditional Chinese Medicine of Xinjiang Medical University, Urumqi City, Xinjiang Uygur Autonomous Region, China.ORCID https://orcid.org/0009-0003-3660-9256
MengTing TongDepartment of Oncology, Affiliated Hospital of Traditional Chinese Medicine of Xinjiang Medical University, Urumqi City, Xinjiang Uygur Autonomous Region, China.ORCID https://orcid.org/0009-0009-1497-9014
WenTing HeDepartment of Oncology, Affiliated Hospital of Traditional Chinese Medicine of Xinjiang Medical University, Urumqi City, Xinjiang Uygur Autonomous Region, China.ORCID https://orcid.org/0009-0002-0451-6664
Nan LiDepartment of Oncology, Affiliated Hospital of Traditional Chinese Medicine of Xinjiang Medical University, Urumqi City, Xinjiang Uygur Autonomous Region, China.ORCID https://orcid.org/0009-0005-2821-0899
YuXiang FanDepartment of Oncology, Affiliated Hospital of Traditional Chinese Medicine of Xinjiang Medical University, Urumqi City, Xinjiang Uygur Autonomous Region, China.ORCID https://orcid.org/0009-0005-5788-7954
YanHua ZhuDepartment of Oncology, Affiliated Hospital of Traditional Chinese Medicine of Xinjiang Medical University, Urumqi City, Xinjiang Uygur Autonomous Region, China.ORCID https://orcid.org/0009-0006-5162-8676
LiPing ZhangDepartment of Oncology, Affiliated Hospital of Traditional Chinese Medicine of Xinjiang Medical University, Urumqi City, Xinjiang Uygur Autonomous Region, China.ORCID https://orcid.org/0009-0000-7626-7308
HongLiang ZhangDepartment of Oncology, Affiliated Hospital of Traditional Chinese Medicine of Xinjiang Medical University, Urumqi City, Xinjiang Uygur Autonomous Region, China.ORCID https://orcid.org/0000-0002-0236-3775
Xinjiang Uygur Autonomous Region Uygur Medicine Hospital · CNXinjiang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/aim: Circular RNAs can serve as detection biomarkers and therapeutic targets for tumors. Our study aimed to elucidate the mechanisms associated with circRNA LDLR (circLDLR) in gastric cancer (GC) proliferation and aerobic glycolysis. Materials and methods: Expression signatures of circLDLR, miR-449b-5p, and CHD1 were examined in GC samples using quantitative PCR. Proliferation ability of MKN-45 cells was assessed via CCK-8 and EdU assays, and cell apoptosis was measured by flow cytometry. Glucose uptake, lactate production, ATP/ADP ratios, and NAD Results: Expression of circLDLR and CHD1 was elevated, while miR-449b-5p expression decreased in GC. Functionally, overexpression of circLDLR enhanced proliferation and aerobic glycolysis and hampered apoptosis of MKN-45 cells. However, upregulation of miR-449b-5p or downregulation of CHD1 reversed these effects. CircLDLR acted as an miRNA spongeand regulated the expression of miR-449b-5p, thereby affecting CHD1 and accelerating GC malignant progression. Conclusion: CircLDLR drives the proliferation and aerobic glycolysis of GC cells by targeting CHD1 with miR-449b-5p, which is an ideal potential target for early diagnosis and clinical treatment of GC.

Indexed as

aerobic glycolysisCHD1CircRNALDLRmiR-449b-5p

Identifiers

PMID38665782
PMCPMC11042865
OpenAlexW4392364769

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.